Adaptive Biotechnologies Corp vs Campbell Soup Co. — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Campbell Soup Co. trades at $22.71 (market cap $6.78B). The key difference: Campbell Soup Co. is the larger of the two by market cap, and Campbell Soup Co. pays a 6.87% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CPB | |
|---|---|---|
Market Cap | $4.04B | $6.78B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $34.03 |
52-Week Low | $12.30 | $20.00 |
Enterprise Value | $4.10B | $13.38B |
Dividend Yield | — | 6.87% |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →